论文部分内容阅读
目的评估盐酸普拉克索联合美多巴治疗血管性帕金森综合征的临床疗效。方法入选134例患者,随机分为吡贝地尔组48例、普拉克索组44例,对照组42例,各组患者诊断符合血管性帕金森综合征的诊断标准,年龄、性别、症状、体征及病程等具有可比性。对照组给予吡贝地尔片、美多巴片,疗程16周;治疗组给予盐酸普拉克索片、美多巴片,疗程16周。并于治疗4、6、16周后观察临床疗效。结果与对照组相比,各治疗组UPDRS评分均有显著性下降(P<0.05),临床疗效明显提高(P<0.05)。与吡贝地尔组相比,普拉克索组显效率(P<0.01)与总有效率均明显优于吡贝地尔组(P<0.05)。结论盐酸普拉克索联合美多巴治疗血管性帕金森综合征效果满意,值得推广应用。
Objective To evaluate the clinical efficacy of pramipexole hydrochloride combined with metopar in the treatment of vascular parkinsonism. Methods A total of 134 patients were enrolled in this study. They were randomly divided into pipeculide group (48 cases), pramipexole group (44 cases) and control group (42 cases). All patients were diagnosed according to the diagnostic criteria of vascular Parkinson’s disease, including age, sex, Signs and duration of comparable. The control group was treated with piribedil and metoprolol for 16 weeks. The treatment group was given pramipexole hydrochloride tablets and metoprolol tablets for 16 weeks. And in the treatment of 4,6,16 weeks after the observation of clinical efficacy. Results Compared with the control group, the UPDRS scores of all treatment groups were significantly decreased (P <0.05), and the clinical efficacy was significantly improved (P <0.05). Compared with the piribedil group, the plexotide (P <0.01) and total effective rate in the pramipexole group were significantly superior to those in the piribedil group (P <0.05). Conclusions Pramipexole Hydrochloride combined with Madopar is effective in the treatment of vascular parkinsonism and it is worth popularizing and applying.